Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Advertisement
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Interview: DKSH Building Healthcare Services In Changing Asian Markets

Market expansion services provider has its headquarters in Switzerland but a long history and most of its business in Southeast Asia, where the global head of its Business Unit Healthcare tells Scrip it continues to build a broad range of services based around knowledge and penetration of local markets.

Asia Pacific Business Strategies

ASLAN, Sosei Pipeline Assets Hit By Development Delays

Two Asia-based companies disclose delays to important clinical pipeline assets, one in oncology driven by apparent ethnic differences in response to prior therapy and the other a CNS molecule hit by an unexpected toxicity finding in an animal study.

Asia Pacific China

Asia Deal Watch: BIOCAD, Shanghai Pharma Agree On Pair Of Russian/Chinese Joint Ventures

The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.

Asia Pacific Deals

Rohto’s Cirrhosis Cell Therapy Finds Japan Partner In Shionogi

In a sign of continued corporate interest in the regenerative and cell therapy area in Japan, Shionogi has acquired rights in this market to a novel cirrhosis treatment being developed by Rohto.

Japan Commercial

Deerfield To Go As Takeda Plans Realignment Of Post-Shire US Ops

Takeda is to close down and relocate one of its main US sites, with unspecified job losses, as it plans post-Shire restructuring, while in Japan vocal opposition to the acquisition rises.

United States Commercial

Dealing With Powerful ‘Vaders’ A Lingering Challenge For Japan’s AMED

Some three and a half years after its formation, Japan’s Agency for Medical R&D (AMED) is continuing its efforts to “de-Balkanize” academic research in the country, and to foster closer health research cooperation between government, academia and industry. While progress has been made, particularly in the genomics area, challenges still linger, its president concedes.

Japan Policy
See All
Advertisement
UsernamePublicRestriction

Register